PMID- 30168260 OWN - NLM STAT- MEDLINE DCOM- 20190528 LR - 20220408 IS - 1756-185X (Electronic) IS - 1756-1841 (Linking) VI - 22 Suppl 1 DP - 2019 Jan TI - Vasculitis research: Current trends and future perspectives. PG - 10-20 LID - 10.1111/1756-185X.13370 [doi] AB - We discuss recent and prospective research in small and large vessel vasculitis. Large cohorts of Takayasu arteritis (TA) have been recently published from across the world, clarifying our understanding of this uncommon disease. Novel open-ended approaches like large-scale genotyping, proteomics and metabolomics have helped gain novel insights into TA, giant cell arteritis (GCA) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Recent advances in the imaging of TA and GCA offer promise for earlier diagnosis and better monitoring of response to therapy. Although two randomized controlled trials of abatacept and tocilizumab failed to meet their primary end-points, successful large-scale studies of abatacept and tocilizumab in GCA hold promise for better disease control. While cyclophosphamide has revolutionized the management of AAV, increasing use of rituximab as an alternative induction regimen, as well as use of novel approaches involving reduced or no corticosteroid use for AAV and alternative agents such as avacopan (a complement 5a receptor antagonist) hold promise for lesser toxic induction regimens in the future. Increasingly, the risk of cardiovascular events and comorbidities such as osteoporosis are being recognized as factors affecting long-term prospects of patients with vasculitis. There is a shift in emphasis to utilize patient-reported outcomes to more accurately gauge the impact of vasculitides and their treatment. CI - (c) 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. FAU - Misra, Durga P AU - Misra DP AUID- ORCID: 0000-0002-5035-7396 AD - Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India. FAU - Naidu, Godasi S R S N K AU - Naidu GSRSNK AD - Department of Internal Medicine, Clinical Immunology and Rheumatology Services, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. FAU - Agarwal, Vikas AU - Agarwal V AUID- ORCID: 0000-0002-4508-1233 AD - Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India. FAU - Sharma, Aman AU - Sharma A AUID- ORCID: 0000-0003-0813-1243 AD - Department of Internal Medicine, Clinical Immunology and Rheumatology Services, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. LA - eng PT - Journal Article PT - Review DEP - 20180830 PL - England TA - Int J Rheum Dis JT - International journal of rheumatic diseases JID - 101474930 RN - 0 (Immunosuppressive Agents) SB - IM MH - Animals MH - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis/drug therapy/epidemiology MH - Biomedical Research/*trends MH - Diffusion of Innovation MH - Forecasting MH - *Giant Cell Arteritis/diagnosis/drug therapy/epidemiology MH - Humans MH - Immunosuppressive Agents/therapeutic use MH - Risk Factors MH - *Takayasu Arteritis/diagnosis/drug therapy/epidemiology MH - Treatment Outcome OTO - NOTNLM OT - ANCA vasculitis OT - Takayasu arteritis OT - eosinophilic granulomatosis with polyangiitis OT - giant cell arteritis OT - granulomatosis with polyangiitis OT - microscopic polyangiitis EDAT- 2018/09/01 06:00 MHDA- 2019/05/29 06:00 CRDT- 2018/09/01 06:00 PHST- 2018/03/05 00:00 [received] PHST- 2018/07/03 00:00 [revised] PHST- 2018/07/25 00:00 [accepted] PHST- 2018/09/01 06:00 [pubmed] PHST- 2019/05/29 06:00 [medline] PHST- 2018/09/01 06:00 [entrez] AID - 10.1111/1756-185X.13370 [doi] PST - ppublish SO - Int J Rheum Dis. 2019 Jan;22 Suppl 1:10-20. doi: 10.1111/1756-185X.13370. Epub 2018 Aug 30.